Organic compounds

Hepatocellular Carcinoma (HCC) Therapy Trends: 2019 KOL Insights -- How Has the Advent of Novel Systemic Therapies Impacted HCC? - ResearchAndMarkets.com

Retrieved on: 
Monday, July 8, 2019
Health, Pharmaceutical, Chemical compounds, Organic compounds, Cancer, Hepatology, Hepatocellular carcinoma, Sorafenib

How has the advent of novel systemic therapies impacted HCC?

Key Points: 
  • How has the advent of novel systemic therapies impacted HCC?
  • Until 2017 the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) was Bayer's Nexavar.
  • Learn how KOLs see the market evolving, and how they expect developers to differentiate their therapies in KOL Insight: Hepatocellular Carcinoma.
  • Do KOLs believe that usage of systemic therapy will change in the future, and what's the potential impact on earlier stages of HCC?

The global proton pump inhibitors (PPIs) market at a CAGR of over 4% during the forecast period

Retrieved on: 
Monday, July 8, 2019
Proton pump inhibitors, Chemical compounds, Organic compounds, Medicine, Gastroenterology, RTT, Pyridines, Sulfoxides, PROTON Holdings, Over-the-counter drug

This proton pump inhibitors (PPIs) market analysis considers sales from Over-the-counter (OTC) PPIs and prescription PPIs.

Key Points: 
  • This proton pump inhibitors (PPIs) market analysis considers sales from Over-the-counter (OTC) PPIs and prescription PPIs.
  • Also, our global proton pump inhibitors (PPIs) market report looks at factors such as reformulation of drugs and growth in prescription rates.
  • The reformulation of already marketed drugs by vendors will lead to the expansion of the global proton pump inhibitors (PPIs) market at a CAGR of over 4% during the forecast period.
  • For the detailed list of factors that will drive the global proton pump inhibitors (PPIs) market during the forecast period 2019-2023, click here.

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

Retrieved on: 
Monday, July 8, 2019
Coagulation system, Blood, Anticoagulants, Chemical compounds, Organic compounds, RTT, Lactams, Factor X, Peripheral membrane proteins, Thrombin, Rivaroxaban, Coagulation

In contrast, data from the same thrombin generation assay demonstrated that Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] fully corrected the inhibition of thrombin generation by apixaban and rivaroxaban across a broad range of inhibitor concentrations.

Key Points: 
  • In contrast, data from the same thrombin generation assay demonstrated that Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] fully corrected the inhibition of thrombin generation by apixaban and rivaroxaban across a broad range of inhibitor concentrations.
  • In this study, tissue factor (TF)-initiated thrombin generation was assessed using plasma from healthy donors or patients treated with warfarin.
  • Finally, the effect of individual purified plasma components of 4F-PCC on thrombin generation in normal plasma was measured.
  • In the U.S. alone in 2017, there were approximately 140,000 hospital admissions attributable to Factor Xa inhibitor-related bleeding.

Zanubrutinib (BeiGene) Overview 2019: An Oral Small Molecule Inhibitor of Bruton's Tyrosine Kinase, Developed to be More Selective with Less Off-Target Effects than Imbruvica - ResearchAndMarkets.com

Retrieved on: 
Monday, July 8, 2019
Genetics, Pharmaceutical, Health, Chemical compounds, Organic compounds, Tyrosine kinase inhibitors, Tyrosine kinases, Acrylamides, Breakthrough therapy, Ibrutinib, Pyrazolopyrimidines, Bruton's tyrosine kinase, Tyrosine kinase, AbbVie Inc.

Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson).

Key Points: 
  • Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson).
  • BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
  • Nonetheless, BeiGene has initiated a Phase III head-to-head trial testing zanubrutinib against Imbruvica.
  • If zanubrutinib can demonstrate statistically significant improvements in efficacy over Imbruvica, the drug could quickly grow to become an important part of the CLL treatment algorithm.

Global Saccharin Market 2019-2023 | 4% CAGR Projection over the Next Five Years | Technavio

Retrieved on: 
Monday, July 8, 2019
Manufacturing, Other Health, Diabetes, Health, Food, Beverage, Retail, Fitness & Nutrition, Chemicals, Plastics, Sugar substitutes, Organic compounds, Ketones, Saccharin, Sulfonamides, Sugar substitute, Market research, Chemistry

The global saccharin market is expected to post a CAGR of close to 4% during the period 2019-2023, according to the latest market research report by Technavio .

Key Points: 
  • The global saccharin market is expected to post a CAGR of close to 4% during the period 2019-2023, according to the latest market research report by Technavio .
  • View the full release here: https://www.businesswire.com/news/home/20190708005308/en/
    Technavio has published a new market research report on the global saccharin market from 2019-2023.
  • (Graphic: Business Wire)
    A key factor driving the growth of the global saccharin market is the increasing demand for low-calorie sweeteners.
  • This global saccharin market 2019-2023 research report also analyzes other significant trends and market drivers that will affect market growth over 2019-2023.

Calquence (acalabrutinib; AstraZeneca/Acerta) Overview and Product profile Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 8, 2019
Health, Pharmaceutical, Clinical medicine, Medicine, Organic compounds, Tyrosine kinase inhibitors, Cancer treatments, Tyrosine kinases, Acrylamides, Breakthrough therapy, Ibrutinib, Bruton's tyrosine kinase, AbbVie Inc., Acalabrutinib

Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity.

Key Points: 
  • Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity.
  • Calquence is being developed for the treatment of various blood cancers and solid tumors, as well as rheumatoid arthritis.
  • If approved, Calquence could potentially be the second BTK inhibitor to reach the market, after AbbVie's Imbruvica (ibrutinib).
  • Calquence will need to show a clear advantage over Imbruvica in terms of efficacy and/or tolerability in order to be successful in the CLL market.

Entrectinib (Roche/Chugai/Nerviano): Global Drug Overview & Outlook with Sales for Non-small Cell Lung Cancer (NSCLC) by Country 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Health, Oncology, Chemical compounds, Tyrosine kinase receptors, Organic compounds, Entrectinib, ROS1, Anaplastic lymphoma kinase, Trk receptor, Tropomyosin receptor kinase B, Protein kinase inhibitor, Tyrosine kinase, Oncogene, Kinase

Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.

Key Points: 
  • Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.
  • Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
  • However, mutations or molecular alterations can result in overactivity, setting off a signal cascade that drives uncontrolled proliferation.
  • In vivo models of entrectinib in TrkB expressing neuroblastoma cells suggest that the drug may enhance the efficacy of conventional chemotherapy.

Lorlatinib (Pfizer) Drug Overview 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Health, Oncology, Chemical compounds, Organic compounds, Protein kinase inhibitors, Tyrosine kinase receptors, Pyridines, Piperidines, ROS1, Lorlatinib, Crizotinib, Anaplastic lymphoma kinase, Entrectinib, Non-small-cell lung carcinoma

Lorlatinib is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity.

Key Points: 
  • Lorlatinib is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity.
  • Genetic alterations to ROS1 and ALK contribute to tumor cell proliferation and survival, and are among the key drivers of tumor development in non-small cell lung cancer (NSCLC).
  • Kinase inhibition through lorlatinib administration leads to disruption of ALK- and ROS1-mediated signaling, and inhibits the growth of tumor cells with ALK and ROS1 overexpression.
  • The drug is also in Phase III development for use in first-line ALK rearrangement-positive NSCLC in a head-to-head trial with Xalkori (crizotinib; Pfizer/Merck KGaA), the historical standard of care in this setting.

Capmatinib (Incyte/Novartis): Global Drug Overview with Sales for Non-Small Cell Lung Cancer (NSCLC) by Country 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Pharmaceutical, Health, Oncology, Lung cancer, Organic compounds, Chemical compounds, Non-small-cell lung carcinoma, Osimertinib, International organizations, European Union

Figure 1: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

Key Points: 
  • Figure 1: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
    Figure 3: Tagrisso sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
    Table 4: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
    Table 5: Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190705005132/en/

New PDFNJ Campaign Highlights Danger of Prescription Opioids

Retrieved on: 
Friday, July 5, 2019
Opioids, RTT, Psychoactive drugs, Organic compounds, Morphine, Euphoriants, Morphinans, Substance dependence, Opioid use disorder, Heroin, Opioid epidemic in the United States, Hyperkatifeia

The campaign features a man trapped in a prescription bottle with the headline: "In just 5 days, opioid dependency can begin."

Key Points: 
  • The campaign features a man trapped in a prescription bottle with the headline: "In just 5 days, opioid dependency can begin."
  • "This message illustrates just how quickly a person can become dependent on opioids," PDFNJ Executive Director Angelo Valente said.
  • "It is crucial that everyone become aware of the dangers of prescription opioids and that they be armed with this knowledge prior to being prescribed opioids for pain.
  • Recent research has found that nearly 80 percent of people who use heroin had reported using prescription opioids prior to using heroin.